Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Eisai Ord Shs ESALF

Healthcare
Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (PINL:ESALF)

Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma

ACN Newswire June 23, 2021

Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate

ACN Newswire June 18, 2021

Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma

ACN Newswire June 14, 2021

Eisai Receives Special Prize at Platinum Career Award 2021

ACN Newswire June 9, 2021

Biogen and Eisai launch initiatives to help patients with Alzheimer's disease access ADUHELM

ACN Newswire June 8, 2021

Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib

ACN Newswire June 7, 2021

Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia

ACN Newswire May 31, 2021

Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting

ACN Newswire May 19, 2021

Eisai and National Cancer Center Commence Joint Research and Development Project

ACN Newswire May 14, 2021
View More News ››

Opinion & Analysis (PINL:ESALF)

No current opinion is available.
View More Opinion ››

Bullboard Posts (PINL:ESALF)

The Worms are out Early - romaorantes

Scam - Watch those with "Zero" stars.  Scam, Multiple handles
Itdontmatter - July 17, 2019
View more Bullboard ››

Nurcapital Corporation Ltd.

Nurcapital Corporation Ltd.

Nurcapital was incorporated under the Business Corporations Act (Ontario) on January 8, 2015. The Company is listed as a ...
View More »